Norge Mining Plc: Publication of Responsible Business Report
1.12.2021 10:00:00 EET | Business Wire | Press release
Norge Mining Plc (“Norge Mining” or the “Company”), the Anglo-Norwegian exploration company developing a world-class resource of Critical Raw Materials in southwest Norway, is pleased to announce publication of its inaugural Responsible Business Report.
The report includes all of the Company’s Environmental, Social and Governance (ESG) information for the year ended 31 December 2020, giving all stakeholders an opportunity to review the Group’s activities and performance.
Norge Mining is committed to sustainable practices and is establishing a range of commitments to align its processes and policies with international guidelines as part of its strategy to build a resilient and robust mining company.
The Company’s Responsible Business Report 2020 can be viewed at this link: https://norgemining.com/wp-content/uploads/2021/11/Norge-Mining_ResponsibleBusinessReport2020_Final_WEB.pdf
The report provides an overview of the Company and a summary of progress at the exciting Bjerkreim Exploration Project, which is focused on the EU Critical Raw Materials vanadium, titanium and phosphate. Resource data published earlier this year gives a total Mineral Resource Estimate at the Bjerkreim project of 1.79 billion tonnes and an Exploration Target of between 2.4 and 4.0 billion tonnes.
John Vergopoulos, Chief Executive Officer of Norge Mining, said:
“As a natural resources company in the early stages of exploration work, we are at the start of an exciting journey towards the mining and processing of critical minerals. We recognise the responsibility that this venture demands and we are determined to embed strong Environmental, Social and Governance principles into our business from the outset and to use innovation to reduce the impact of our activities. We are pleased to publish our inaugural Responsible Business Report and welcome comments from all stakeholders.”
About Norge Mining plc
Norge Mining plc is an Anglo-Norwegian natural resources company focused on mineral exploration in Norway.
The Company’s first Mineral Resource Estimates from the Bjerkreim Exploration Project have confirmed world-class deposits of the EU Critical Raw Materials vanadium, titanium and phosphate. The provenance of these materials is of significant strategic importance for net carbon zero commitments, a key requirement for which is supply chain transparency.
Norge Mining, which owns 61 exploration licences totalling more than 520,000 square kilometres in southwest Norway, is currently conducting a programme of exploration work, building on earlier studies by the Norway Geological Survey (NGU). The Company’s ambition is to become a substantial, sustainable and strategically important exploration and mining business focused on Norway.
Founded in November 2018, the Company is headquartered in the UK and has a 100%-owned Norwegian subsidiary, Norge Mineraler AS.
For further information, please visit www.norgemining.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005942/en/
Contact information
For media enquiries, please contact:
Buchanan Communications
Mark Court / James Husband
+44 (0) 20 7466 5000
norgemining@buchanan.uk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 22:11:00 EEST | Press release
Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to further extend its category leadership among legal-age consumers of nicotine products. Like the flagship FDA-authorized ZYN pouches, ZYNULTRA, with its higher moisture content, is fre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom